Sunday, October 25, 2009
EMERGENCY UPDATE, SWEDEN: FOUR DEATHS LINKED TO THE H1N1 VACCINE AS OF OCTOBER 24, 2009. From Jane Burgermeister's website, THE FLU CASE: updates, country by country.
The news that a fourth person has died after taking the "swine flu" jab in Sweden is focussing attention on the failure of the Swedish Medical Products Agency (MPA) to halt the "swine flu" programme even as reports of serious side effects flood in.
The Swedish drug regulator has allowed the "swine flu" jab campaign to be launched even though there is no safety or efficacy data on the vaccine. GlaxoSmithKline's Pandemrix with mercury and squalene has been given approval under new and lax European Union regulations formulated by the European Medicines Agency, (EMEA) for a "pandemic emergency" that do not require safety or efficacy data.
The EMEA derives three-quarters of its funding from pharmaceutical companies.
The "swine flu" jab has been authorised for use only on condition that governments and companies implement "post-authorisation" studies to check it is safe and effective. However, the MPA in Sweden appears to have limited its role in collecting data on death and damage to spontaneous reports from doctors and patients.
In addition, there appears to be no accurate data available on how many people have been given the "swine flu" jab in Sweden.
The MPA has said it has no such data and the SMI has said that its system for collecting data on vaccines is flawed.
EU's own guidelines on "post authorisation" studies highlight the need to collect accurate data on "vaccine exposure".
( NB, apparently the patients were high risk, DS)
"The only study on Pandemrix will be carried out in the UK."
You bet it will. Because here we have totally corrupt "rent a researcher" doctors on every corner.
Plus no one ever takes reports of side effects seriously here now matter how bad they are. They are masters of the cover up.
Look up Aubrey Blumsohn and Actinel. The only unusual thing about that case was that one of the doctors refused to have "his" results dictated by the Pharma company. He lost his job.
The UK medical profession has many excellent doctors and a few decent people left. But all those in positions of power are bought and sold and have no interest except doing what their paymasters dictate. It might be giving unnecessary treatment as in this case or it might be withholding cheap safe treatments because the drug companies make much more money from treating the symptoms than treating the disease.
The Pharma companies target "key opinion leaders" and make them offers they can't refuse. They make sure doctors in their control get professional advancement because the more powerful the doctor the more powerful his controllers. This is well known, a report was made for the UK government about it but they decided not to do anything.
( frankly I do NOT like posting this flag on my blog, but the information is important)
ON ANOTHER NOTE, IN GERMANY,
"30-year-old Hadnet Tesfai tested the "swine flu" vaccine planned for use on "lowly commoners", as Bild puts it, referring to the fact that high government officials are getting a different jab without mercury and adjuvants."
Schweinegrippe-Impfung BILD.de-Moderatorin Hadnet Tesfai (30) noch immer müde
Deutschland droht eine Schweinegrippe-Welle ungeahnten Ausmaßes – doch nur ein Bruchteil der Bürger scheint die Gefahr ernst zu nehmen. Viele fürchten sich mehr vor eventuellen Nebenwirkungen der Impfung, als vor dem Killer-Virus selbst!
Mittlerweile gibt es in Deutschland ein drittes Todesopfer. Experten befürchten sogar bis zu 35 000 Tote, wenn die Grippe-Saison erst richtig losgeht.
BILD wollte es genau wissen – und hat den Impfstoff für die „gemeine“ Bevölkerung schon mal vorab getestet.
Ergebnis: Leichte Schmerzen an der Einstichstelle, Müdigkeit, leichter Schüttelfrost. Gravierende Folgen? Bislang Fehlanzeige!
BILD.de-Moderatorin Hadnet Tesfai (30) führt darüber hinaus exklusiv einen Video-Blog über die Folgewirkungen.
Auch sie fühlt vor allem Müdigkeit, die Muskelschmerzen haben stark nachgelassen. Dafür erwartet unsere Kollegin morgen ein echter Härtetest ...
WHILE IN FRANCE, DR. MENGELE STYLE SELECTION....
The letter from Health Minister Roselyn Bachelot -- who airbrushed her 12 years of employment for pharmacuetical companies from her government CV -- falsely claims the jab is "safe and efficacious" when the EMEA itself say that safety and efficacy have not been proven.
The coupon lists several different makes of swine flu jabs including Baxter's Celvapan and Novartis's Celtura, even though has no EU-wide marketing approval, and which appears to be the repacked Aflunov, responsible for killing people in Poland in 2008.
Sanofi's Panenza appears to be the only vaccine without adjuvants and to be made in the same way as the seasonal flu - that is to say it is well tested and probably the "secret tip" of the French elite.
This prepared coupon could be a ticket to death for some depending on the choice of vaccine, antigen dose and adjuvant made by the government.
MEANWHILE IN SWITZERLAND...:
The government realizes that their beloved NOVARTIS HAS CREATED A DOG OF A VACCINE - WHATEVER HAPPENED TO SWISS QUALITY???
Problems with authorisation of Novartis "swine flu" jab Celtura in Switzerland
Last Updated on Sunday, 25 October 2009 11:30
According to the report from the print edition, dated Saturday 24th October (Schweinegrippe: Novartis hat Problem mit Impfstoffzulassung) tests on Celtura found that the dog based cell vaccine was contaminated with bacteria from dogs.
The Swiss government had ordered 5 million doses of Celtura, a drug that appears to be a repacked version of Aflunov/Fluad H5N1, which seems to have been responsible for killing people in Poland in clinical trials in 2008.
Click on the article for a larger version.
[and besides, LET'S NOT FORGET THE ADJUVANT MF59 IN THE VACCINE, NO DIFFERENT THAN THE ADJUVANT IN GLAXO'S PANDEMRIX - SAME LONG-TERM ADVERSE EFFECTS EXPECTED, DS]
AND CANADA, AS USUAL, FOLLOWS THE BRITISH CROWN WITH THE GLAXO POISON: SHAME ON YOU, CANADA; I WOULD HAVE EXPECTED BETTER OF YOU!
Canada approves Arepanrix "swine flu" jab with adjuvants
Friday, 23 October 2009 12:31
OTTAWA - Minister of Health Leona Aglukkaq today announced that Health Canada has approved AREPANRIX, a vaccine against the pandemic H1N1 flu virus.
This means that the adjuvanted vaccine has been judged safe and effective for use in Canada by both the Canadian manufacturer, GlaxoSmithKline, as well as by the Health Canada regulator.
"This is a milestone in our efforts to fight the pandemic H1N1 flu virus,"said Minister Aglukkaq.
"Thanks to careful planning we now have a safe and effective vaccine being distributed to provinces and territories that they will be rolling out in a matter of days. I encourage all Canadians to get vaccinated because it is the best way to protect our health and the health of our loved ones."
Health Canada and the Public Health Agency of Canada are currently working with provincial and territorial governments to deliver the H1N1 flu vaccine to health care facility sites to begin immunization programs.
"Canada is in the enviable position to be able to offer vaccine to every citizen who needs and wants it,"said Canada's Chief Public Health Officer, Dr. David Butler-Jones.
"Getting the vaccine is the most effective way we know of to curb the spread of the pandemic H1N1 flu virus. I too encourage all Canadians to get the pandemic H1N1 flu vaccine when it becomes available in their provinces and territories."
The Chief Public Health Officer also noted that the Public Health Agency of Canada, Health Canada and the regulatory and public health agencies of other countries, are working together to ensure that appropriate control measures are in place to monitor the safety and effectiveness of the vaccine and to ensure the timely communication of any potential adverse events following immunization. There is also a global commitment amongst regulatory authorities to rapidly share clinical and safety data on H1N1 flu vaccines and on any potential adverse events following immunization.
National recommendations on the use of H1N1 flu vaccine have been developed based on the latest scientific evidence, including clinical trial results. The recommendations include:
- All Canadians 10 years of age and older should receive one dose of adjuvanted vaccine;
- Children from six months and up to 10 years of age should receive the adjuvanted vaccine in two half-doses, administered at least 21 days apart;
- Children age 0-6 months – immunization not authorized; and
- Pregnant women should receive one dose of the unadjuvanted vaccine, of which Canada has ordered 1.8 million doses. In cases where the unadjuvanted vaccine is unavailable and pandemic H1N1 flu rates are high or increasing in the community, women more than 20 weeks pregnant should be offered one dose of the adjuvanted vaccine.
For more information on the pandemic H1N1 flu vaccine, visit www.fightflu.ca.